MindRank Shares Oral GLP-1RA MDR-001 Clinical Data at LSX World Congress, Emphasizing AI-Driven Innovation

Posted on by

HANGZHOU, China and LONDON, Sept. 18, 2025 — MindRank, a drug discovery company utilizing artificial intelligence (AI) in its clinical stages, presented at the 2025 LSX World Congress in Boston. The company’s keynote presentation, “AI-Designed Oral GLP-1RA: First-in-Class Phase IIb Clinical Readouts and Translational Insights,” featured the first international presentation of updated clinical results for MDR-001, which generated considerable interest among industry experts and corporate leaders.

MDR-001, an AI-designed oral GLP-1 receptor agonist (GLP-1RA), has the potential to be a first-in-class drug, representing a significant advancement in drug discovery. It highlights how AI can transform traditional R&D methods and broaden the scope of AI applications within the pharmaceutical industry.

MindRank’s AI drug discovery platform facilitated the discovery of MDR-001. Phase IIb clinical trials revealed a statistically significant weight reduction of 10.3% at 24 weeks with MDR-001, compared to 2.5% with placebo (p<0.00001). Notably, 48.1% of participants achieved ≥10% weight loss, and placebo-adjusted weight loss ranged from 7.1% to 7.8%. MDR-001 exhibited a favorable safety and tolerability profile, with no treatment-related serious adverse events (SAEs) reported and a significantly lower discontinuation rate compared to the 15%–50% typically seen in GLP-1 therapy clinical trials[1,2]. These results suggest that MDR-001 may lead to better patient adherence and promising clinical benefits. The liver safety profile was generally positive, even with about 20% of study participants having pre-existing liver dysfunction and elevated transaminase levels. No transaminase elevation trends were observed across all groups. Furthermore, MDR-001 treatment groups showed significant reductions in transaminase levels from baseline, compared to the placebo group.

MindRank emphasized the potential of AI in target identification, molecular design, and optimization, as demonstrated by the swift progress and favorable results of MDR-001. AI is transforming the future of drug discovery by accelerating R&D timelines, lowering costs, and increasing success rates. MindRank’s appearance at the LSX World Congress underscored the capabilities of its AI platform, the clinical promise of MDR-001, and garnered recognition from the global biopharmaceutical community, marking a key advancement in the company’s international strategy.

References：

[1] Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art. Molecular metabolism, 46, 101102.

[2] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-2b-results-oral-glp-1r

About MDR-001

MDR-001 is a new, orally available small-molecule GLP-1 RA that selectively targets β-arrestin 2. It was discovered using MindRank’s proprietary AI platform, Molecule Pro™. MDR-001 has shown strong functional potency and selectivity, good ADME properties and oral bioavailability, and favorable pharmacokinetics, safety, and tolerability, indicating it could be a best-in-class treatment for obesity and T2DM, which have significant unmet medical needs.

About MindRank

MindRank is a drug discovery company that uses artificial intelligence (AI). The company aims to speed up the drug discovery process and create differentiated small molecule medicines with clinical advantages by utilizing its proprietary AI platforms (PharmKG™, Molecule Dance™ and Molecule Pro™). MDR-001, the company’s main asset, is an AI-designed oral GLP-1RA small molecule that has successfully finished a phase 2b clinical study.

For more information, visit www.mindrank.ai.

For BD inquiries, contact bd@mindrank.ai.

“`